BridgeBio Oncology Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing small-molecule oncology programs for RAS and PI3Kα malignancies. Its 8-K reports cover material events such as leadership and board changes, compensatory arrangements, clinical-data press releases, and operating or financial results.
Proxy materials describe annual meeting matters, director elections, board classification, auditor ratification, and governance practices. The company’s filings also identify its common stock capital structure and formal disclosure categories for clinical and regulatory updates, governance, compensation, and public-company reporting obligations.
BridgeBio Oncology Therapeutics, Inc. (BBOT) is filing Post-Effective Amendment No. 2 to convert an existing Form S-1 into a Form S-3 shelf registration for the resale of up to 63,054,549 shares of common stock by selling securityholders. No additional securities are being registered, and all registration fees were previously paid.
The registered shares include PIPE shares issued in a February 2025 private financing, shares issued to the SPAC sponsor and initial holders, shares issued or issuable to prior equity holders in the August 2025 business combination with Helix Acquisition Corp. II, and shares issuable upon exercise of options. BBOT will not receive proceeds from resale of these shares, but may receive up to $8.37 million in cash if all 1,907,207 registered options are exercised. BBOT is a clinical-stage biotechnology company focused on small-molecule therapeutics targeting RAS and PI3K, with multiple candidates holding FDA Fast Track designations.
BridgeBio Oncology Therapeutics, Inc. filed a prospectus supplement covering the resale of 63,054,549 shares of common stock by selling securityholders and incorporating its latest quarterly report for the period ended June 30, 2026. The stock trades on Nasdaq under the symbol BBOT; the August 11, 2026 closing price was $9.20 per share.
As of June 30, 2026, the company reported $376.7 million in total assets, including $344.1 million in cash, cash equivalents, and marketable securities, and stockholders’ equity of $323.1 million. It recorded a net loss of $56.5 million for the quarter and $98.6 million for the first half of 2026, bringing accumulated deficit to $455.1 million. Operating cash outflows were $80.3 million for the six months, and the company stated that existing cash, cash equivalents, and marketable securities are expected to fund operations for at least one year from the financial statement issuance date.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage oncology company focused on RAS and PI3K malignancies, reported a larger net loss as it ramped development after its 2025 de‑SPAC transaction. For the three months ended June 30, 2026, net loss was $56.5 million, compared with $28.4 million a year earlier; for the first half of 2026, net loss was $98.6 million versus $50.5 million in 2025. Operating expenses doubled year over year, driven by research and development of $49.2 million in the quarter and general and administrative of $11.0 million, including higher public‑company and stock‑based compensation costs.
Despite higher spending, BridgeBio Oncology reported strong liquidity. As of June 30, 2026, cash, cash equivalents, and marketable securities totaled $344.1 million, within total assets of $376.7 million, and the company had 80.1 million common shares outstanding. Management states this cash position is expected to support operations for at least one year from the financial statement issuance date, but the company anticipates continued losses and negative operating cash flows as it advances its pipeline, and it expects to seek additional financing through equity, debt, or partnering arrangements.
BridgeBio Oncology Therapeutics, Inc. reported second quarter 2026 results and provided an update on its RAS-pathway oncology pipeline. The company is advancing three wholly owned clinical programs: BBO-8520 (KRAS G12C inhibitor), BBO-11818 (pan-KRAS inhibitor targeting KRASG12D/V), and BBO-10203 (blocking RAS–PI3Kα interaction) in multiple monotherapy and combination cohorts, including combinations with pembrolizumab, cetuximab, tucatinib, trastuzumab and internal combinations of its own assets.
As of June 30, 2026, cash, cash equivalents and marketable securities totaled $344.1 million, which management expects to fund operations into 2028. Second quarter 2026 research and development expenses were $49.2 million and general and administrative expenses were $11.0 million, both higher than the prior-year quarter, reflecting increased clinical and manufacturing activity and the start of standalone, post–de-SPAC operations. Net loss for the quarter was $56.5 million, with an accumulated deficit of $455.1 million and total stockholders’ equity of $323.1 million.
BridgeBio Oncology Therapeutics, Inc. principal accounting officer Marc Cobo reported a routine tax-related share disposition. On the vesting of restricted stock units, the company withheld 125 shares of Common Stock to cover his tax obligations, rather than selling them in the open market. Following this withholding, Cobo directly holds 5,306 shares of Common Stock.
BridgeBio Oncology Therapeutics, Inc. reported a routine insider equity event for COO & Principal Financial Officer Elmelech Idan. The company withheld 343 shares of Common Stock at $7.80 per share to cover his tax obligations tied to vesting restricted stock units. This was a tax-withholding disposition, not an open-market trade, and reflects how part of his equity award was used to pay taxes. After this withholding, Idan directly holds 14,495 shares of the company’s common stock.
BridgeBio Oncology Therapeutics, Inc. Chief Medical & Development Officer Ben Yong had 1,047 shares of common stock withheld on July 1, 2026 to cover tax obligations tied to vesting restricted stock units. This was an automatic tax-withholding disposition at $7.80 per share, not an open-market trade. After this transaction, Yong directly owned 44,576 shares of BridgeBio Oncology common stock.
BridgeBio Oncology Therapeutics, Inc. reported that President and CEO Pedro Beltran had 1,047 shares of Common Stock withheld by the company at $7.80 per share to cover tax obligations from vesting restricted stock units. After this withholding, he directly holds 44,576 shares of Common Stock. This was a tax-withholding disposition, not an open-market sale.
BridgeBio Oncology Therapeutics, Inc. received an Amendment No. 3 to a Schedule 13D from Cormorant-affiliated investors led by Bihua Chen. The reporting group now shows beneficial ownership of 17,878,594 shares of common stock, or 22.32% of the company’s 80,107,104 shares outstanding as of the latest 10-Q.
The update reflects a pro rata distribution of 4,528,186 shares by Helix Holdings II LLC to its members, after which Helix holds no shares. Fund III, Fund V, and the Master Fund each received additional shares and entered a joinder to the existing lock-up agreement covering these distributed shares. The filing also notes that director Bihua Chen was granted 31,675 stock options at an exercise price of $7.73, which remain unvested.
BridgeBio Oncology Therapeutics, Inc. director and 10% owner Bihua Chen reported indirect ownership changes tied to a restructuring among investment vehicles associated with Helix Holdings II LLC, the Sponsor. The filing shows a pro rata distribution of 4,528,186 common shares from the Sponsor to its members for no consideration.
According to the footnotes, Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare Fund V, LP, and Cormorant Global Healthcare Master Fund, LP each received shares in this pro rata distribution, and Cormorant Private Healthcare Fund IV, LP is also managed by the same investment manager. Post-transaction indirect holdings include 1,905,046 shares via Fund IV and 6,083,221 shares via the Master Fund. The transactions are classified as "other" (code J), reflect internal allocations with no open-market buying or selling, and include disclaimers that Ms. Chen and the funds only beneficially own securities to the extent of their pecuniary interests.